Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

ACCG-2671

First-in-human Study of the Safety, Tolerability, Pharmacokinetics, and Food Effect of ACCG-2671

Aconcagua Bio, Inc · Phase 1/2 · Recruiting · Enrollment 164

NCT07815678

Participants reaching a weight loss threshold

Participants reaching threshold, %

Source: Cited trial source. The denominator is the source figure, when it states one.

No selected arm reports a responder percent.

Show as table
Arm≥5%≥10%≥15%≥20%
Part 1 (SAD)n/rn/rn/rn/r
Placebo Part 1 (SAD)n/rn/rn/rn/r
Part 2 (Food-effect)n/rn/rn/rn/r
ACCG-2671 Part 3 (MAD)n/rn/rn/rn/r
Placebo Part 3 (MAD)n/rn/rn/rn/r

Not shown

  • Part 1 (SAD): endpoint not reported
  • Placebo Part 1 (SAD): endpoint not reported
  • Part 2 (Food-effect): endpoint not reported
  • ACCG-2671 Part 3 (MAD): endpoint not reported
  • Placebo Part 3 (MAD): endpoint not reported